SpeeDx Preps to Launch Meningitis MDx Test in 2015

Monday, December 29, 2014

Source: Genome Web

Australian molecular diagnostics company SpeeDx is picking up the pace on its path to the clinic, the firm reports.

Founded on proprietary nucleic acid enzymes called MNAzymes and unique primer and isothermal signaling technologies, the company has pursued parallel paths — co-developing diagnostics with licensees and nurturing its own IVD pipeline.

Now, the company expects an undisclosed licensee to launch a CE-marked in vitro diagnostic in Q2 of 2015, and SpeeDx itself will follow with a multiplexed meningitis diagnostic later in the year. The company also published two studies of its technologies late last year and collaborated with Biocartis on cancer-related mutation detection.

View All News »